View Older Stories View More Recent Stories
-
Johnson & Johnson to acquire Halda Therapeutics for $3.05 billion
-
Judge denies Texas AG's TRO against Kenvue over Tylenol marketing
-
FDA approves DARZALEX FASPRO for high-risk smoldering multiple myeloma
-
Johnson & Johnson seeks FDA approval for STELARA in pediatric ulcerative colitis
-
HHS Secretary Kennedy on Tylenol: not enough evidence to show Tylenol definitively causes autism but some studies seem 'very suggestive'
-
Johnson & Johnson initiates first head-to-head FcRn blocker study for myasthenia gravis
-
Texas attorney general sues Johnson & Johnson and Kenvue over Tylenol marketing
-
Johnson & Johnson reports extended trial results for ulcerative colitis drug
-
TREMFYA shows sustained remission in Crohn's disease at two years
-
Johnson & Johnson reports 52-week psoriasis trial results for icotrokinra
-
Freedom Capital Markets Downgrades Johnson & Johnson (JNJ) to Hold
-
Stifel Reiterates Bicara Therapeutics Inc (BCAX) at Buy, Still Confident of Ficerafusp Thesis
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
J&J drug combination shows survival benefits in myeloma study
-
Johnson & Johnson (JNJ) PT Raised to $201 at Leerink Partners, 'Improving Growth Prospects'
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $209 at Raymond James
-
Johnson & Johnson (JNJ) PT Raised to $225 at Wolfe Research
-
Johnson & Johnson (JNJ) PT Raised to $190 at Stifel
-
Johnson & Johnson (JNJ) PT Raised to $215 at Citi
-
CFRA Upgrades Johnson & Johnson (JNJ) to Buy
-
Johnson & Johnson (JNJ) call put ratio 2 calls to 1 put amid plans to separate Orthopaedics business and quarter outlook
-
J&J raises revenue guide as Q3 tops forecasts, plans to spin off Orthopaedics unit
-
Johnson & Johnson (JNJ) call put ratio 2.1 call to 1 put into plans to separate Orthopaedics business
-
Johnson & Johnson plans to separate orthopaedics unit DePuy Synthes
-
Johnson & Johnson (JNJ) to separate orthopaedics business into standalone business operating as Depuy Synthes
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 4c; lifts guidance
-
Jefferies flags Q3 earnings upside for this pharma giant as key drugs outperform
-
Protagonist Therapeutics (PTGX) Said to Be Mentioned Cautiously Regarding M&A
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put into quarter results
-
Johnson & Johnson (JNJ) October straddle priced into quarter results
-
Protagonist Therapeutics (PTGX) PT Raised to $112 at BMO Capital
-
Protagonist Therapeutics stock surges after J&J acquisition talks report
-
Protagonist Therapeutics (PTGX) halted on volatility
-
Johnson & Johnson (JNJ) in talks to buy Protagonist Therapeutics (PTGX) - WSJ
-
Johnson & Johnson (JNJ) October 200 and 210 calls active into quarter results
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $212 at Goldman Sachs
-
Johnson & Johnson (JNJ) ordered to pay $966M after California jury finds company liable for woman's cancer in talc case - court filing
-
Johnson & Johnson icotrokinra meets primary endpoint in ulcerative colitis trial
-
Johnson & Johnson reports TREMFYA subcutaneous ulcerative colitis data
-
Johnson & Johnson reports contact lens study results at optometry meeting
-
Johnson & Johnson (JNJ) PT Raised to $200 at Wolfe Research
-
Johnson & Johnson (JNJ) PT Raised to $193 at Bernstein SocGen Group
-
UBS on why it's still not ready to push the buy button on pharma stocks
-
Wells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside
-
Johnson & Johnson (JNJ) call put ratio 3.5 calls to 1 put with a focus on January 180 and April 185 calls
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
